BioUtah News
-
The Teva Turnaround: Steering a Company Comeback
CEO Richard Francis reflects on Teva’s return to growth during his tenure, and what’s next for the drugmaker…
-
Craig-Hallum Initiates Myriad Genetics Stock with a Buy Rating
Craig-Hallum Initiates Myriad Genetics Stock with a Buy Rating
-
bioMérieux receives U.S. FDA clearance for the new version of its molecular test targeting causes of gastroenteritis, BIOFIRE® FILMARRAY® Gastrointestinal (GI) Panel Mid
bioMérieux receives U.S. FDA clearance for the new version of its molecular test targeting causes of gastroenteritis, BIOFIRE®…
-
EVŌQ Nano Secures Strategic Investment From Global Business Leader & Philanthropist Tony Robbins to Advance Next-Generation Antimicrobial Nanoparticle Technology
EVŌQ Nano Secures Strategic Investment From Global Business Leader & Philanthropist Tony Robbins to Advance Next-Generation Antimicrobial Nanoparticle…
-
Denali Therapeutics Announces Primary Analysis and Long-Term Follow-Up of Phase 1/2 Study in Hunter Syndrome (MPS II) with Tividenofusp Alfa
Denali Therapeutics Announces Primary Analysis and Long-Term Follow-Up of Phase 1/2 Study in Hunter Syndrome (MPS II) with…
-
Nelson Labs Leuven Unveils Cutting-Edge Analytical Upgrade for Non-Volatile Extractables & Leachables Screening
Nelson Labs Leuven Unveils Cutting-Edge Analytical Upgrade for Non-Volatile Extractables & Leachables Screening
-
Recursion Presents Phase 2 Data for REC-994 in CCM in Late-Breaking Oral Presentation at the International Stroke Conference
Recursion Presents Phase 2 Data for REC-994 in CCM in Late-Breaking Oral Presentation at the International Stroke Conference
-
Dr. Robert Langer and Brigadier General Larry Lunt Join Forces with Sethera
World-Renowned Scientist and Co-founder of Moderna, Dr. Robert Langer, to Guide Sethera’s Scientific Strategy; Brigadier General Larry V.…
-
Myriad Genetics and CancerCARE for Life Announce Agreement to Advance Access to MyRisk with RiskScore Hereditary Cancer Test
Myriad Genetics and CancerCARE for Life Announce Agreement to Advance Access to MyRisk with RiskScore Hereditary Cancer Test
-
Myriad Genetics and Lumea Collaborate to Enhance Access to the Prolaris Biomarker and MyRisk Hereditary Cancer Tests through BxLink Integration
Myriad Genetics and Lumea Collaborate to Enhance Access to the Prolaris Biomarker and MyRisk Hereditary Cancer Tests through…
-
Myriad Genetics Announces Two New Patents Granted for its Molecular Residual Disease (MRD) Assay
Myriad Genetics Announces Two New Patents Granted for its Molecular Residual Disease (MRD) Assay
-
Tasso and ARUP Laboratories Announce Partnership, Combined Offering for Decentralized Clinical Research Biomarker Testing
The partnership combines Tasso’s clinical grade blood collection solutions, such as the Tasso+ device pictured above, with ARUP’s…
-
PhotoPharmics Announces Leadership Transition in Clinical & Scientific Advisory Board
PhotoPharmics Announces Leadership Transition in Clinical & Scientific Advisory Board
-
Owlet Unveils ‘Owlet360’ – Turning Infant Health Data Into Peace of Mind for Parents
This new subscription service, exclusive to Owlet users, gives parents a deeper, personalized understanding of their baby’s development,…
-
Myriad Genetics Unveils Groundbreaking Eight Weeks’ Gestation NIPT Study Results at Society for Maternal-Fetal Medicine Conference
Opening plenary session features latest fetal fraction amplification research
-
Life Sciences Day on the Hill 2025
The Capitol Rotunda was filled with exhibits from over 25 local life sciences companies.
-
Kelvyn Cullimore Joins KSL Radio’s Inside Sources
SALT LAKE CITY, January 23, 2025—Today BioUtah president and CEO Kelvyn Cullimore joined KSL Radio’s Inside Sources to discuss…
-
Ultradent Donating to Southern California Fire Relief
Ultradent Donating to Southern California Fire Relief
-
Canyon Labs Announces Strategic Acquisition of iuvo BioScience’s Lab Services and Consulting Businesses to Expand End-to-End Development Solutions
Transaction positions iuvo BioScience for continued growth as an industry leader in ophthalmic clinical research
-
Denali Therapeutics Announces U.S. FDA Breakthrough Therapy Designation Granted to Tividenofusp Alfa for the Treatment of Hunter Syndrome (MPS II)
Denali expects to submit a Biologics License Application for tividenofusp alfa in early 2025 for regulatory review under…
-
Recursion Announces Two Key Investigational Oncology Drugs Advancing to Clinical Trials, Targeting High Unmet Needs in Hematologic Malignancies, Small-Cell Lung Cancer, & More
Recursion Announces Two Key Investigational Oncology Drugs Advancing to Clinical Trials, Targeting High Unmet Needs in Hematologic Malignancies,…
-
MD Anderson and Myriad Genetics form strategic alliance to evaluate clinical utility of Myriad’s molecular residual disease assay
MD Anderson and Myriad Genetics form strategic alliance to evaluate clinical utility of Myriad’s molecular residual disease assay
-
M42’s IROS and Halia Therapeutics launch clinical study on obesity treatment in the UAE
Trial underscores IROS’s commitment to developing innovative therapies for unmet medical needs
-
ARUP Offers New Assay To Detect Influenza A (H5) Virus
SALT LAKE CITY, January 3, 2025—ARUP Laboratories today launched a new assay for the detection and subtyping of influenza…
-
Sethera Therapeutics Completes First Funding Round
Sethera Therapeutics Completes First Funding Round
-
Sorriso Pharmaceuticals Announces Positive Phase 1b Clinical Trial Results for SOR102 in Ulcerative Colitis
Data from Dual-Acting Oral Biologic Show Promising Safety and Efficacy Profile
-
CancerVax Passes First Test with Flying Colors
Recent in-vitro lab results confirm that the Company’s Smart mRNA can be used as a potential on/off switch…
-
Merit Medical Announces FDA Approval of the WRAPSODY Cell-Impermeable Endoprosthesis
Unique cell-impermeable1 design extends life-saving treatment for dialysis patients.
-
Here’s how Utah earned its No. 1 ranking for innovation
A new report from the U.’s Kem C. Gardner Policy Institute uncovers the wide-ranging mechanisms driving Utah’s high…
-
Teva Announces New Patient Access Program with Direct Relief to Provide Access to Inhalers for Uninsured Patients
Teva to provide two generic inhaler products to Direct Relief for its network of free and charitable clinics.…
-
Myriad Genetics’ RiskScore Study Named One of the Top 10 Significant Advances in Genomic Medicine in American Journal of Human Genetics
Study Demonstrates RiskScore as a More Accurate Predictor of Breast Cancer Risk, Doubling Accuracy Compared to the Tyrer-Cuzick…
-
Human Forms and Body Parts Trigger Strong Reactions in the Brain
Human Forms and Body Parts Trigger Strong Reactions in the Brain
-
Canary Speech and Prism Care Announce Partnership to Enhance Extended Care Through Vocal Biomarker Technology
Partnership aims to set new industry standards for managing mental health and cognitive conditions
-
SINTX TECHNOLOGIES SECURES PATENT ALLOWANCE FOR WIDE-RANGING SILICON NITRIDE BIOMATERIAL APPLICATIONS
SINTX TECHNOLOGIES SECURES PATENT ALLOWANCE FOR WIDE-RANGING SILICON NITRIDE BIOMATERIAL APPLICATIONS
-
BD Resolves Previously Disclosed SEC Investigation
BD has reached an agreement with the U.S. SEC to resolve the previously disclosed investigation related to prior…
-
NUSANO NAMES MEDICAL RADIOISOTOPES ADVISORY BOARD
VALENCIA, Calif. – Dec. 3, 2024 – Nusano, a physics company transforming the production of radioisotopes, today announced…
-
Co-Diagnostics, Inc. and CoSara Diagnostics to Inaugurate New Oligo Facility
SALT LAKE CITY, Dec. 10, 2024 /PRNewswire/ — Co-Diagnostics, Inc. (Nasdaq: CODX) (the “Company” or “Co-Dx”), a molecular diagnostics company with…
-
Halia Therapeutics Announces Positive Topline Data and Advances to Second Stage of Phase 2 Clinical Trial for HT-6184 in Patients with Low-Risk Myelodysplastic Syndromes (LR-MDS)
LEHI, Utah, Dec. 10, 2024 /PRNewswire/ — Halia Therapeutics, a biopharmaceutical company at the forefront of developing treatments…
-
Recursion Reports Interim Phase 1 Clinical Data for REC-617 Monotherapy, a Potential Best-in-Class CDK7 Inhibitor, With Encouraging Patient Response and Favorable Tolerability
Recursion reported initial monotherapy dose-escalation data from the Phase 1/2 study (ELUCIDATE) of REC-617, a selective CDK7 inhibitor,…
-
CancerVax Targets Hard to Treat Pancreatic Cancer
With limited options available to treat Pancreatic Ductal Adenocarcinoma (PDAC), the Company’s Universal Cancer Treatment Platform may provide…
Call to Action
Post Category
- BioUtah COVID-19 Analysis
- BioUtah News
- Business Tools & Resources
- Call to Action
- COVID-19 Legislation
- COVID-19 Updates
- Economic Developments
- Events
- Events
- Feature
- Featured Members
- Federal News
- Funding
- Funding
- Guests Posts
- HHS/FDA & Other Regulatory
- HR
- Industry News
- Life Sciences Events
- Life Sciences Industry News
- Newsletters
- Non-chair
- Policy News
- Press Releases
- State News
- Utah's Life Sciences Companies
- Workplace Safety
Latest Posts
- Lumea Named Best New Biopsy Technology Solution in 2026 MedTech Breakthrough Awards
- Co-Diagnostics Develops Ebola Assay Strategy Following Recent Global Outbreak Alert
- BlueWind Medical Secures $47.8M Financing to Accelerate Commercialization of Revi® System
- PhotoPharmics Announces Last Patient Last Visit in Pivotal, Phase 3, Light for PD Clinical Trial…
- AFTER SUCCESSFUL FDA MEETING, CLENE FILING ACCELERATED APPROVAL NDA FOR ALS
